Pharmaceutical biotechnology

This session centers on pharmaceutical biotechnology, offering a structured look at advances in pharmaceutical biotechnology, including how biologic drugs like recombinant proteins, monoclonal antibodies, gene therapies and vaccines are developed using living systems. We will discuss the scientific and technological breakthroughs that enable large scale production and the complexities of manufacturing and quality control unique to biologics. Challenges such as stability, immune responses, and high manufacturing costs will be addressed, along with emerging solutions like biosimilars and innovations in gene editing and precision medicine. Finally, we'll consider the evolving regulatory landscape and its role in ensuring these therapies are safe, effective, and accessible. Pharmaceutical biotechnology has revolutionized medicine development, providing new tools to address previously intractable conditions. Unlike traditional small molecule drugs, biotech harnesses living systems to create therapies such as recombinant proteins, monoclonal antibodies, gene therapies and vaccines. This field encompasses core scientific principles, technological breakthroughs, and challenges involved in bringing these biologic drugs from the laboratory to patient care. At the heart of pharmaceutical biotechnology is recombinant DNA technology, which enables insertion of human genes into host cells, such as bacteria, yeast, or mammalian lines to produce human proteins at scale.